drug for ovarian cancer
Last Updated : GMT 09:07:40
Egypt Today, egypt today
Egypt Today, egypt today
Last Updated : GMT 09:07:40
Egypt Today, egypt today

By up to six months

Drug for ovarian cancer

Egypt Today, egypt today

Egypt Today, egypt today Drug for ovarian cancer

Drug can slow progress of ovarian cancer
London - Arabstoday

Drug can slow progress of ovarian cancer London - Arabstoday A drug can slow down the progress of ovarian cancer – known as the’ silent killer’ – by up to six months, claim researchers. A new trial of 1,500 women shows Avastin delays the advance of the disease by an average of two months, compared with standard chemotherapy. But women with the most aggressive disease got the biggest benefit, with the disease stalled for almost six months. Avastin, also known as bevacizumab, is already widely used in patients with colon cancer, and doctors believe it will become a standard treatment for ovarian cancer. Chief investigator Dr Tim Perren, Consultant Oncologist from St James’s Institute of Oncology, St James’s University Hospital, Leeds and Honorary Senior Lecturer at the University of Leeds, said: ‘These results are potentially very encouraging particularly for women with advanced ovarian cancer. ‘Bevacizumab is the first new drug for 15 years to show an advantage over existing treatments for women with this disease. ‘These results are however preliminary and will not be fully confirmed until early 2013.’ Ovarian cancer, which affects almost 7,000 women a year, is dubbed the ‘silent killer’ because symptoms are often diagnosed too late. About 4,400 women die each year from the disease, which claims the lives of over 85 per cent of patients if found at a late stage when it has spread to other parts of the body. There has been little improvement in overall survival rates since the introduction of the chemotherapy drug paclitaxel 15 years ago. Latest findings from an international trial sponsored by the UK Medical Research Council are published in The New England Journal of Medicine. The trial followed 1.528 ovarian cancer patients who were randomly allocated to receive either standard chemotherapy, or a combination of standard treatment and Avastin, following surgery to remove their tumour. The researchers recorded the time taken for the disease to return, measured by CT scan. The interim results of the trial, reported after 28 months of follow-up, show an overall slowing down of disease progression by around two months. The results suggest it may improve overall survival in women, and the biggest effect on delaying the disease was found in women with an aggressive form of the disease – by almost six months. Professor Max Parmar, director of the MRC Clinical Trials Unit and co-author of the study, said ‘This suggests that bevacizumab could be considered as a treatment for women with an advanced form of the disease, or whose cancer has come back after chemotherapy treatment. ‘However, the decision on whether to include the drug routinely should be delayed until we have further evidence on its impact on overall survival.’ Avastin is a ‘targeted’ cancer therapy that works by blocking the development of new blood vessels and interfering with the tumour’s ability to grow and spread to other parts of the body. Combining the drug with chemotherapy has been shown to improve the effectiveness of treatment in several other forms of the disease including lung, kidney and colorectal cancers, although it has proved to be less effective than hoped in breast cancer. Annwen Jones, chief executive of Target Ovarian Cancer, said ‘It is very exciting and positive news for women living with ovarian cancer in the UK. It is the first glimmer of hope that there are significant advancements in treatments for ovarian cancer on the horizon at last. ‘We said previously the real challenge was to find well-tolerated treatments that prolong the lives of women, and it seems that Avastin is now a significant step nearer to realising that goal.’ Roche, which manufactures the drug, has applied to the European Medicines Agency for a licence to use it to treat ovarian cancer and a decision is expected shortly. It will need to be approved by the NHS rationing body, Nice, before it is widely used but in the meantime cancer specialists can apply for funding on behalf of patients to the Cancer Drugs Fund in England.  

egypttoday
egypttoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

drug for ovarian cancer drug for ovarian cancer



GMT 06:29 2011 Monday ,14 November

Matthew cruises to win at Ochoa Invitational

GMT 03:34 2017 Wednesday ,22 March

Tillerson to skip NATO meeting next month

GMT 13:44 2013 Friday ,15 March

Israel suppress Palestinian demonstrations

GMT 16:15 2017 Monday ,01 May

Moroccan Workers’ Syndicate

GMT 11:56 2016 Wednesday ,12 October

Toyota, Suzuki eye partnership as industry consolidates

GMT 15:42 2011 Thursday ,23 June

Express checks in with foursquare

GMT 10:49 2017 Sunday ,13 August

Car rams into crowd at violent Virginia rally

GMT 17:45 2013 Sunday ,20 October

5 Indian spices that are good for your health

GMT 08:41 2012 Saturday ,15 September

Italian magazine: will print Kate topless snaps

GMT 08:02 2012 Tuesday ,05 June

Zoe Saldana in Prabal Gurung
 
 Egypt Today Facebook,egypt today facebook  Egypt Today Twitter,egypt today twitter Egypt Today Rss,egypt today rss  Egypt Today Youtube,egypt today youtube  Egypt Today Youtube,egypt today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

egypttoday egypttoday egypttoday egypttoday
egypttoday egypttoday egypttoday
egypttoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
egypttoday, Egypttoday, Egypttoday